^
    Back
    Association details:
    Biomarker:RB1 mutation + TP53 mutation
    Cancer:Urothelial Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Cancer
    Title:

    RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

    Published date:
    04/20/2021
    Excerpt:
    RB1&TP53 samples had the highest response rate to atezolizumab....RB1&TP53 co-alterations are strongly associated with genomic biomarkers of response to ICIs in MIBCs.
    DOI:
    10.1186/s12885-021-08078-y